US Regulators Approve ‘Game-Changing’ Type 1 Diabetes Drug
Type 1 diabetes affects about 8.7 million people around the world.
View Source | November 18, 2022 12:34 am
- A new immunotherapy drug that delays the development of type 1 diabetes was given the green light by U.S. regulators.
- Teplizumab focuses on addressing the root cause of the condition, rather than the symptoms, which experts say ushers in a “new era” in treatment.
- The drug works by reprogramming the body’s immune system and preventing it from mistakenly attacking pancreatic cells, which produce insulin.
Click to read full article
Go back home
Share This Article: